Vericel's change in inventory for the quarter that ended in Mar. 2026 was $-1.0 Mil. It means Vericel's inventory
increased by $1.0 Mil
from Dec. 2025 to Mar. 2026 .
Vericel's change in inventory for the fiscal year that ended in Dec. 2025 was $-1.2 Mil. It means Vericel's inventory
increased by $1.2 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Vericel's Days Inventory for the quarter that ended in Mar. 2026 was 85.52.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Vericel's Inventory Turnover for the quarter that ended in Mar. 2026 was 1.07.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vericel's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.26.
Vericel (NAS:VCEL) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Vericel's Days Inventory for the quarter that ended in is calculated as:
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vericel's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel Change In Inventory Related Terms
Vericel Change In Inventory Historical Data
* Premium members only.
The historical data trend for Vericel's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $-2.5 Mil mean?
Vericel (VCEL) has a Change In Inventory of $-2.5 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Vericel and its competitors.
Is Vericel's Change In Inventory too high?
Vericel's current Change In Inventory is $-2.5 Mil. Overall, Vericel has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's Change In Inventory compare to NRIX and MLYS?
Vericel's Change In Inventory of $-2.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Vericel and its competitors. Vericel's current Change In Inventory is $-2.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $54.78, compared to a current price of $46.98 — trading 14.2% below its estimated fair value. The current Change In Inventory is $-2.5 Mil. Vericel's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Vericel (VCEL), the current Change In Inventory is $-2.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (VCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of $46.98 is trading 14.2% below its estimated GF Value™ of $54.78.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for VCEL:
Change In Inventory: $-2.5 Mil
GF Value™: $54.78 vs. price of $46.98 (14.2% below fair value)
No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
81GF Score
Get the complete analysis for VCEL
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCEL has been successfully added to your 
